News

Investors who watch AT&T (NYSE: T) closely know that it has spent the last two years atoning for a costly mistake. It not only strayed from its core service offerings but also overpaid to enter the

Telecom giant AT&T (NYSE: T) has a very simple story now that it's shed its ambitions to become a media conglomerate. The core business is wireless, which will grow slowly at best. The secondary

The various market indexes are all positive so far in 2023, but the rebound is not universal and there's no shortage of stocks still trading near their lows. A couple of struggling stocks that

Last year wasn't the best year for tech stocks, with many seeing drops into double-digit percentages. Luckily, 2023 has been much better. The tech-heavy Nasdaq Composite -- which tracks almost all

First Horizon (NYSE: FHN) saw its stock price rise 13.7% this week, as of Friday's opening bell, according to S&P Global Market Intelligence. The stock had been up as much as 14.7% during the week

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If

Telecom giant AT&T (NYSE: T) is best known today as a leading wireless provider in the United States, but it's also investing heavily in fiber internet. The company now has 7.5 million fiber

Shares of Summit Therapeutics (NASDAQ: SMMT) were down more than 13% on Tuesday. The biotech company's shares have been trending downward since it released first-quarter earnings late last week. On

Shares of Horizon Therapeutics (NASDAQ: HZNP), a rare disease specialist, were down by 17.4% on heavy volume as of 10:14 a.m. ET Tuesday morning. The drugmaker's shares are falling after news broke

Investing in high-yield dividend stocks for income is one thing, but getting a high yield at a great valuation can be a formula for long-term success when it comes to investing. In this video, we

Raise your hand if you've heard that telecom giant AT&T (NYSE: T) stock has been cheap before. Shares have been getting cheaper for years -- Ma Bell's stock price is down 40% over the past decade.

Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. And smaller companies that lack any approved

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been

The biggest disappointment from AT&T's (NYSE: T) first-quarter earnings report was its dismal free cash flow.

Free cash flow is extremely important for AT&T investors, many of whom look for the

Shares of Summit Therapeutics (NASDAQ: SMMT) were up by 61.4% for the week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence. The healthcare stock, which

Image source: The Motley Fool.

Amarin Plc (NASDAQ: AMRN)Q1 2023 Earnings CallMay 03, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the